Neurocrine Biosciences, Inc. NBIX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.98% | 34.42% | 28.59% | 21.45% | 19.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.98% | 34.42% | 28.59% | 21.45% | 19.61% |
| Cost of Revenue | 32.46% | 29.26% | 26.74% | 39.30% | 37.52% |
| Gross Profit | 41.19% | 37.44% | 29.64% | 12.86% | 11.21% |
| SG&A Expenses | 19.13% | 19.43% | 16.78% | 16.48% | 23.57% |
| Depreciation & Amortization | 2,470.00% | 1,640.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.60% | 24.76% | 21.46% | 26.53% | 29.78% |
| Operating Income | 77.93% | 73.37% | 54.85% | 6.50% | -8.09% |
| Income Before Tax | 48.28% | 78.37% | 101.09% | 45.14% | 20.51% |
| Income Tax Expenses | 14.46% | 31.26% | 67.64% | 56.74% | 47.83% |
| Earnings from Continuing Operations | 64.14% | 102.56% | 118.64% | 40.23% | 10.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.14% | 102.56% | 118.64% | 40.23% | 10.91% |
| EBIT | 77.93% | 73.37% | 54.85% | 6.50% | -8.09% |
| EBITDA | 83.20% | 72.97% | 52.22% | 6.70% | -7.12% |
| EPS Basic | 61.95% | 102.44% | 120.51% | 41.73% | 11.36% |
| Normalized Basic EPS | 62.17% | 61.79% | 48.99% | 6.60% | -6.53% |
| EPS Diluted | 61.19% | 101.71% | 119.92% | 41.52% | 11.91% |
| Normalized Diluted EPS | 61.16% | 60.96% | 48.98% | 6.72% | -5.88% |
| Average Basic Shares Outstanding | 1.23% | 0.25% | -0.70% | -0.92% | -0.50% |
| Average Diluted Shares Outstanding | 1.86% | 0.75% | -0.73% | -1.21% | -1.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |